Contract development and manufacturing services for chemicals, particularly in pharmaceuticals and specialties.
chemXplore tracks 59 projects in CDMO, of which 14 are active.
8 expansion, 5 new construction, and 1 revamp / retrofit.
1 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (4), Lonza (2), AGC Biologics S.p.A. (1), AMSilk GmbH (1), Ajinomoto Foods Europe (1), Biovac (1)
Investors: Evonik Industries AG (2), AGC Group (1), AMSilk GmbH (1), Ajinomoto Co., Inc. (1), Ajinomoto Foods Europe (1), European Investment Bank (1)
Licensors and offtakers are recorded on 5 of these 14 projects For subscribers
Feasibility study to combine Fol‑Dab8 (folate‑conjugated cationic peptide) with naturally occurring microRNA for oligonucleotide therapeutics; undisclosed equity investment made.
€15m first tranche of a €35m package to expand a Colombian plant to produce up to 250m doses annually, plus a €1.5m R&D grant for three vaccine candidates.
Passed a two-week unannounced FDA GMP inspection covering drug substance and drug product manufacturing, reinforcing U.S. commercial supply reliability.
Shows preservative solutions for pet care, launches biodegradable Cosmelin esters as a silicone alternative, presents Scopeblue lower‑carbon preservatives and an Oct 16 LCA talk.
Aligns businesses by role, assigns roles to six German sites, and shifts investment to Asia/Americas; launches growth projects in Canada and Slovakia, funded by cost cuts.
First subcutaneous immune‑checkpoint inhibitor in Japan; can be given in as little as one minute and showed comparable exposure and response to IV pembrolizumab in a phase‑3 trial.
EUR 80m upgrade adds downstream fermentation capacity for complex pharma intermediates, targets completion early 2028 and about 50 new jobs; site runs on 100% green electricity.
Framework to boost EU production capacity, guide R&D and investments, and reduce dependence on Russian isotopes and HALEU.
Joint research will advance manufacturing, automation and quality-control for cell and gene therapies to expand Japan's manufacturing infrastructure and patient access.
New plant adds clinical-scale lipid nanoparticle drug product capacity with federal support; production is planned to start at the end of 2029.
By country, the most active first. active / all projects
The 8 with the most active projects, of 22 countries.
